| scholarly article | Q13442814 |
| P50 | author | Robert L Findling | Q90314248 |
| James M. Swanson | Q109401078 | ||
| Laurence L Greenhill | Q109420186 | ||
| P2093 | author name string | ADHD Study Group | |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | attention | Q6501338 |
| placebo | Q269829 | ||
| attention deficit hyperactivity disorder | Q181923 | ||
| P304 | page(s) | E39 | |
| P577 | publication date | 2002-03-01 | |
| P1433 | published in | Pediatrics | Q7159238 |
| P1476 | title | A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder | |
| P478 | volume | 109 |
| Q42848612 | A Double-Blind, Randomized, Placebo/Active Controlled Crossover Evaluation of the Efficacy and Safety of Ritalin®LA in Children with Attention-Deficit/Hyperactivity Disorder in a Laboratory Classroom Setting |
| Q46863548 | A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder |
| Q38164670 | A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). |
| Q41448511 | ADHD in children: a path to free medicines. |
| Q37085902 | Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. |
| Q39293219 | An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments |
| Q38214174 | An evaluation of the pharmacokinetics of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder |
| Q35233563 | An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety |
| Q57581441 | Attention and Executive Disorders in Neurofibromatosis 1: Comparison Between NF1 With ADHD Symptomatology (NF1 + ADHD) and ADHD Per Se |
| Q43045659 | Attention deficit disorder and hyperactivity: does the treatment affect the statural growth? |
| Q57400259 | Attention-deficit hyperactivity disorder |
| Q37784796 | Cardiovascular Effects of Methylphenidate, Amphetamines and Atomoxetine in the Treatment of Attention-Deficit Hyperactivity Disorder |
| Q37793743 | Changes in emotions related to medication used to treat ADHD. Part I: literature review |
| Q91605833 | Chronic oral methylphenidate treatment increases microglial activation in rats |
| Q35477867 | Clinical use of a modified release methylphenidate in the treatment of childhood attention deficit hyperactivity disorder |
| Q48604793 | Cognitive Testing to Identify Children With ADHD Who Do and Do Not Respond to Methylphenidate |
| Q38930427 | Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison |
| Q30374187 | Comparing Auditory Noise Treatment with Stimulant Medication on Cognitive Task Performance in Children with Attention Deficit Hyperactivity Disorder: Results from a Pilot Study. |
| Q24685027 | Comparing the efficacy of medications for ADHD using meta-analysis |
| Q43274881 | Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis |
| Q38443741 | Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with Attention Deficit/Hyperactivity Disorder |
| Q38101134 | Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate |
| Q35042691 | Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement |
| Q37898791 | Controversies surrounding pediatric psychopharmacology |
| Q38019961 | Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review |
| Q30391541 | Differences in Speech Recognition Between Children with Attention Deficits and Typically Developed Children Disappear When Exposed to 65 dB of Auditory Noise. |
| Q39834928 | Does Prior Exposure to Stimulants in Children with ADHD Impact Cardiovascular Parameters from Lisdexamfetamine Dimesylate? |
| Q45164077 | Does a morning dose of Methylphenidate Retard reduce hyperkinetic symptoms in the afternoon? |
| Q35970045 | Dose response effects of lisdexamfetamine dimesylate treatment in adults with ADHD: an exploratory study |
| Q35676640 | Economic implications of attention-deficit hyperactivity disorder for healthcare systems |
| Q50675975 | Effects of methylphenidate on acute math performance in children with attention-deficit hyperactivity disorder. |
| Q22241427 | Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults |
| Q46584563 | Efficacy and Tolerability of Different Interventions in Children and Adolescents with Attention Deficit Hyperactivity Disorder |
| Q24805432 | Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data |
| Q37654952 | Estimating the size of treatment effects: moving beyond p values |
| Q34303865 | Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children |
| Q40198244 | Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD. |
| Q24653919 | Hypericum perforatum (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial |
| Q52029707 | Impulsivity among adolescents with ADHD and bronchial asthma. |
| Q46438027 | Individual change in methylphenidate use in a national sample of children aged 2 to 11 years |
| Q36471058 | Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline |
| Q46486344 | Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guidelines. Part 2: a quantitative evaluation of long-acting medications |
| Q38401702 | Memantine versus Methylphenidate in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Double-Blind, Randomized Clinical Trial |
| Q42170001 | Meta-Analysis: Reduced Risk of Anxiety with Psychostimulant Treatment in Children with Attention-Deficit/Hyperactivity Disorder |
| Q36622139 | Methylphenidate controlled-delivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder |
| Q37898763 | Methylphenidate delivery mechanisms for the treatment of children with attention deficit hyperactivity disorder: heterogeneity in parent preferences |
| Q22061981 | Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) |
| Q33209665 | New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential |
| Q45293740 | New long-acting stimulants in children with ADHD. |
| Q33976616 | Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate |
| Q44371105 | Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats |
| Q36715371 | Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action |
| Q36693016 | Pharmacological management of attention-deficit hyperactivity disorder in adolescents: special considerations |
| Q36468087 | Pharmacotherapy for childhood obesity: present and future prospects |
| Q22241419 | Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents |
| Q22242745 | Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder |
| Q44807396 | Production of extended release mini-tablets using directly compressible grades of HPMC. |
| Q30449130 | Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I. |
| Q30451303 | Safety of stimulant treatment in attention deficit hyperactivity disorder: part II. |
| Q36825927 | Sensitivity of scales to evaluate change in symptomatology with psychostimulants in different ADHD subtypes |
| Q36729625 | Spotlight on methylphenidate controlled-delivery capsules (Equasym XL, Metadate CD) in the treatment of children and adolescents with attention-deficit hyperactivity disorder |
| Q37069181 | Stimulant treatment in children with attention-deficit/hyperactivity disorder moderates adolescent academic outcome |
| Q61795760 | Subjective and objective assessments of sleep problems in children with attention deficit/hyperactivity disorder and the effects of methylphenidate treatment |
| Q34233624 | The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial. |
| Q45164082 | The effectiveness of stimulants of retard forms in children and adolescents with ADHD--a systematic overview |
| Q39546891 | The prototype/willingness model, academic versus health-risk information, and risk cognitions associated with nonmedical prescription stimulant use among college students |
| Q38082894 | Toward quality care in ADHD: defining the goals of treatment |
| Q34025768 | Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation |
| Q47414856 | Understanding the Effect Size of Lisdexamfetamine Dimesylate for Treating ADHD in Children and Adults |
| Q24642024 | Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths |
| Q30596479 | What influences clinicians' decisions about ADHD medication? Initial data from the Influences on Prescribing for ADHD Questionnaire (IPAQ). |
Search more.